Provider Update for Oncology
Welcome to Provider Update
This edition of our Provider Update touches on three very timely topics: the role of our oncology outreach team for adult and pediatric cancers; two important clinical trials focused on myelodysplastic syndromes; and research on a new drug to fight oral premalignant lesions. <Read More>
Oncology outreach: Making the right connection
At University of Minnesota Medical Center, Fairview, the oncology outreach team is there to help you make the right connections, and to foster the relationships between you and University of Minnesota Physicians’ oncology specialists.
<Read More>
Diabetes drug may show promise for oral premalignant lesions
Pioglitazone, a drug currently used to treat type 2 diabetes, is being studied for its possible effect on oral premalignant lesions, perhaps even reducing the risk of mouth cancer. A Phase IIB randomized, placebocontrolled trial is underway at the University of Minnesota. .<Read More>
New myelodysplastic syndrome research now underway at the University of Minnesota
Researchers at the University of Minnesota are working on two large research studies related to myelodysplastic syndrome (MDS). <Read More>
Receive Provider Update by Email
Sign up now to receive Provider Update electronically
